BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
BRAF inhibitor monotherapy appears to be ineffective in BRAF (V600E)-positive colorectal cancer (CRC) as a result of inherent EGFR-mediated resistance mechanisms. This concept initiated combinatorial treatment approaches. Nevertheless, BRAF inhibition in isogenic CRC cell lines induced enhanced cell-cell adhesion and differentiation, underlining a potential benefit of BRAF inhibitors in CRC.
Institute of Molecular Medicine and Cell Research (IMMZ); Albert-Ludwigs-University (ALU); Freiburg, Germany; University Medical Center, ALU; Freiburg, Germany.
Ricarda
R
Herr
Institute of Molecular Medicine and Cell Research (IMMZ); Albert-Ludwigs-University (ALU); Freiburg, Germany; University Medical Center, ALU; Freiburg, Germany; Centre for Biological Signaling Studies BIOSS, ALU; Freiburg, Germany.
Tilman
T
Brummer